Tobetsa mona ho bonts'a lifolakha tsa HAO leqepheng lena mme u lefelle katleho feela

Litaba tsa mohala

Sethethefatsi se Secha sa Patlisiso bakeng sa Bakuli ba Acute Myeloid Leukemia

ngotsoeng ke mohlophisi

Priothera Ltd. kajeno e phatlalatsa hore Tsamaiso ea Lijo le Lithethefatsi ea US (FDA) e fane ka tumello ea ho tsoela pele ka kopo ea Khamphani ea Investigational New Drug (IND) ho qala thuto ea eona ea bohlokoa ea Phase 2b/3 ea mocravimod (e bitsoang MO-TRANS).

Priothera e tla qala thuto ea MO-TRANS ea Phase 2b/3 ea lefats'e Europe, US le Japane, ho lekola ts'ebetso le polokeho ea mocravimod e le pheko e thusang le tlhokomelo ho bakuli ba baholo ba Acute Myeloid Leukemia (AML) ba kenang allogenic hematopoietic stem cell transplant (HSCT). ). Boithuto ba MO-TRANS bo lebelletsoe ho qala halofong ea bobeli ea 2022 mme lintlha tsa pele tse tsoang phuputsong ena li lebelletsoe bofelong ba 2024.

Allogenic stem cell transplantation ke eona feela mokhoa o ka folisang bakuli ba AML, leha ho le joalo likhetho tsa hajoale tsa kalafo li ntse li amahanngoa le palo e phahameng ea litla-morao, le litekanyetso tse phahameng tsa ho shoa. 

Florent Gros, Mothehi-mmoho le CEO oa Priothera, o ile a fana ka maikutlo a hore "Tlhaloso ea FDA IND ea ho qala thuto ea MO-TRANS e hlahlobang mocravimod ho bakuli ba AML ba tlas'a allogeneic HSCT ke ketsahalo e 'ngoe ea bohlokoa bakeng sa Priothera. Re mocheng oa ho qala teko ena ea bohlokoa ea Phase 2b/3 'me re lebelletse ho sebetsa le sehlopha se seholo sa bafuputsi ba chesehang ho pholletsa le US, Europe le Asia, ba arolelanang sepheo sa rona sa ho tlisa mocravimod ho bakuli e le kalafo ea tlatsetso le tlhokomelo. bakeng sa AML le mafu a mang a ka bang teng a hematologic.

Litaba Tse Amanang

Mabapi le mongoli

mohlophisi

Mohlophisi e moholo oa eTurboNew ke Linda Hohnholz. O lula ntlong e kholo ea eTN e Honolulu, Hawaii.

Leave a Comment

Arolelana ho...